XML 14 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)
Preferred Stock [Member]
Common Stock [Member]
Common stock issuable [Member]
Additional Paid-in Capital [Member]
Subscription receivable [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2020 $ 33,912 $ 24,315 $ 340,000 $ 11,898,441   $ (12,359,680) $ (63,012)
Balance, shares at Dec. 31, 2020 395,640 282,735 1,556        
Share based compensation 246,966   246,966
Shares issued due to private placement $ 10,320 9,098,828   9,109,148
Shares issued due to private placement, shares   120,000          
Net income (loss)   (613,926) (613,926)
Shares issued for services $ 86 90,964   91,050
Shares issued for services, shares   1,000          
Over-allotment shares from offering, net of offering costs of $250,928 $ 1,548 1,364,825   1,366,373
Over-allotment shares from offering, net of offering costs, shares   18,000          
Warrants sold during public offering at quoted price   20,700   20,700
Shares issued due to conversion of preferred stock $ (33,812) $ 22,618 11,194  
Shares issued due to conversion of preferred stock, shares (394,493) 262,995          
Shares issued due to conversion of debt $ 3,631 3,796,369   3,800,000
Shares issued due to conversion of debt, shares   42,222          
Rounding shares related to initial public offering  
Rounding shares related to initial public offering, shares   126        
Shares issued pursuant to software purchase $ 134 $ (340,000) 339,866   0
Shares issued pursuant to software purchase, shares   1,556 1,556        
Shares issued pursuant to software purchase, shares   (1,556) (1,556)        
Balance at Mar. 31, 2021 $ 100 $ 62,652 26,868,153   (12,973,606) 13,957,299
Balance, shares at Mar. 31, 2021 1,147 728,634        
Balance at Dec. 31, 2021 $ 62,815 27,329,201 $ (20,000,000) (33,458,145) (26,066,129)
Balance, shares at Dec. 31, 2021 730,407        
Share based compensation 739,960 739,960
Shares issued due to private placement $ 781 $ 15,313 (16,043) 20,000,000 20,000,051
Shares issued due to private placement, shares 9,076 178,059        
Shares issued pursuant to acquisition of Medigap $ 3,475 4,759,976 4,763,451
Shares issued pursuant to acquisition of Medigap, shares   40,402          
Exercise of Series A warrants $ 2,150 2,472,850 2,475,000
Exercise of Series A warrants, shares   25,000          
Issuance of prefunded Series C Warrants in exchange for common shares $ (18,788) 18,788
Issuance of prefunded Series C Warrants in exchange for common shares, shares   (218,462)          
Shares issued for vested stock awards $ 34 (34)
Shares issued for vested stock awards, shares   400          
Net income (loss) 9,340,000 9,340,000
Balance at Mar. 31, 2022 $ 781 $ 64,999 $ 35,304,698 $ (24,118,145) $ 11,252,333
Balance, shares at Mar. 31, 2022 9,076 755,806